Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).
Clinical trial NCT05219162 · COMPLETED
Trial details
- NCT number
- NCT05219162
- Sponsor
- AstraZeneca
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-25
- Primary completion
- 2024-04-29
- Enrollment
- 182
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.